Lantern Pharma (LTRN) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free LTRN Stock Alerts $5.46 +0.08 (+1.49%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineH.C. Wainwright Keeps Their Hold Rating on Lantern Pharma (LTRN)markets.businessinsider.com - April 25 at 8:11 PMLantern Pharma (NASDAQ:LTRN) Given Neutral Rating at HC Wainwrightmarketbeat.com - April 25 at 8:31 AMLantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Developmentfinance.yahoo.com - April 24 at 9:04 AMLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Developmentbusinesswire.com - April 24 at 8:00 AMLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwanbusinesswire.com - April 22 at 8:12 AMLantern Pharma Inc. (LTRN)finance.yahoo.com - April 17 at 2:21 PMLantern Pharma Inc Ordinary Sharesmorningstar.com - April 13 at 10:13 AMLantern Pharma (NASDAQ:LTRN) Trading Down 13.8%marketbeat.com - April 12 at 12:55 AMShort Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Expands By 191.1%marketbeat.com - April 12 at 12:14 AMLantern Pharma Inc (LTRN)investing.com - April 10 at 1:29 PMLantern Pharma Inc. to Post FY2024 Earnings of ($2.06) Per Share, HC Wainwright Forecasts (NASDAQ:LTRN)marketbeat.com - March 21 at 8:06 AMLantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 20 at 7:31 PMLantern Pharma Inc. (NASDAQ:LTRN) Expected to Earn Q1 2024 Earnings of ($0.43) Per Sharemarketbeat.com - March 20 at 5:45 AMLTRN: 2023 Resultsmsn.com - March 19 at 6:11 PMH.C. Wainwright Reaffirms Their Hold Rating on Lantern Pharma (LTRN)markets.businessinsider.com - March 19 at 1:10 PMLantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 19 at 1:10 PMLTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023investorplace.com - March 18 at 10:00 PMRecap: Lantern Pharma Q4 Earningsbenzinga.com - March 18 at 7:43 PMLantern Pharma Inc Reports Progress and Financials for FY 2023finance.yahoo.com - March 18 at 7:43 PMLantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlightsbusinesswire.com - March 18 at 4:02 PMLantern Pharma (LTRN) to Release Earnings on Mondaymarketbeat.com - March 17 at 1:23 AMLantern Pharma Inc. (NASDAQ:LTRN) Short Interest Updatemarketbeat.com - March 16 at 11:05 PMLantern Pharma Up 20% After Dosing Initiated in Trial for Cancer Drug Developed with AImarketwatch.com - March 16 at 10:04 PMLTRN May 2024 5.000 callfinance.yahoo.com - March 16 at 5:03 PMLTRN Apr 2024 12.500 callfinance.yahoo.com - March 16 at 7:01 AMLantern Pharma Earnings Previewbenzinga.com - March 15 at 4:00 PMLantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284finance.yahoo.com - March 15 at 10:59 AMLTRN Mar 2024 10.000 callfinance.yahoo.com - March 14 at 10:35 PMLantern Pharma (LTRN) to Release Quarterly Earnings on Mondaymarketbeat.com - March 12 at 9:59 AMLantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ETbusinesswire.com - March 11 at 7:30 AMLTRN Oct 2024 5.000 putfinance.yahoo.com - March 8 at 2:55 PMLTRN Apr 2024 2.500 callfinance.yahoo.com - March 8 at 2:55 PMLTRN Mar 2024 7.500 callfinance.yahoo.com - March 7 at 1:08 PMLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conferencefinance.yahoo.com - March 5 at 8:39 AMLantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conferencebusinesswire.com - March 5 at 8:01 AMLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelinesfinance.yahoo.com - March 4 at 12:37 PMAfter Taiwan's striking lantern festival, school kids help clean up the messmsn.com - February 28 at 2:01 AMLantern Pharma Stock (NASDAQ:LTRN) Dividends: History, Yield and Datesbenzinga.com - February 23 at 8:54 AMLTRN: Spotlighting ADCs & Another Orphanfinance.yahoo.com - February 20 at 1:05 PMLantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancersfinance.yahoo.com - February 15 at 9:47 AMLantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancersbusinesswire.com - February 15 at 8:01 AMHere's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situationfinance.yahoo.com - February 5 at 4:01 PMStarlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officerfinance.yahoo.com - January 17 at 9:28 AMLantern Pharma: FDA Grants Orphan Drug Designation For LP-284 In High-Grade B-cell Lymphomasmarkets.businessinsider.com - November 30 at 12:26 PMFDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)finance.yahoo.com - November 30 at 12:26 PMLantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 10 at 3:01 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Lantern Pharma (LTRN), LifeMD (LFMD) and Calliditas Therapeutics (CALT)markets.businessinsider.com - November 9 at 11:57 PMLTRN: Three Assets in the Clinic in 3Q:23finance.yahoo.com - November 9 at 1:56 PMLantern Pharma GAAP EPS of -$0.29msn.com - November 8 at 7:42 PMLantern Pharma: Q3 Earnings Insightsbenzinga.com - November 8 at 7:42 PM Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea. Click here to find out what to do. LTRN Media Mentions By Week LTRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LTRN News Sentiment▼0.070.37▲Average Medical News Sentiment LTRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LTRN Articles This Week▼61▲LTRN Articles Average Week Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EGRX News MURA News CELU News IMMX News HCWB News EQ News KZR News MNOV News SCYX News RLYB News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LTRN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
